-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E3211KhFlOWw9w8xd0PvQWsY+G7TqxO4xdiill/bS+FqFfKh7A1qrNSRQEOfFmnX R/BHOfRBfFiBc7EeckKicg== 0000950153-02-001034.txt : 20020528 0000950153-02-001034.hdr.sgml : 20020527 20020528163430 ACCESSION NUMBER: 0000950153-02-001034 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20020528 ITEM INFORMATION: Other events FILED AS OF DATE: 20020528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICIS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000859368 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521574808 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14471 FILM NUMBER: 02663660 BUSINESS ADDRESS: STREET 1: 8125 NORTH HAYDEN ROAD CITY: SCOTTSDALE STATE: AZ ZIP: 85258 BUSINESS PHONE: 2125992000 MAIL ADDRESS: STREET 1: 8125 NORTH HAYDEN ROAD CITY: SCOTTSDALE STATE: AZ ZIP: 85258 8-K 1 p66647e8vk.htm 8-K e8vk
Table of Contents

 

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8–K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): May 28, 2002

Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)

         
Delaware   0-18443   52-1574808
(State or Other Jurisdiction of
Incorporation)		   (Commission File Number)   (IRS Employer Identification No.)
     
8125 North Hayden Road
Scottsdale, Arizona		    
85258-2463
(Address of Principal
Executive Offices)		   (Zip Code)
     
Registrant’s telephone number, including area code   (602) 808-8800

 

Item 5. Other Events.
SIGNATURES
EX-99.1

Table of Contents

Item 5.   Other Events.

         On May 28, 2002, we issued a press release announcing that we intend to raise up to $350 million in aggregate principal amount of our Contingent Convertible Senior Notes due 2032 (the “Notes”) in a private placement pursuant to Rule 144A promulgated under the Securities Act of 1933, as amended. The initial purchaser of the Notes will have the option to purchase up to an additional $50 million in aggregate principal amount of the Notes. The sale of the Notes is expected to close on or about June 4, 2002. We expect to use the net proceeds from the offering of the Notes:

  •   to fund the purchase of $125 million of shares of our Class A common stock sold short by purchasers of the Notes concurrently with their purchase of the Notes;
 
  •   for future acquisitions; and
 
  •   for general corporate purposes.

         A copy of the press release appears as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

 

Table of Contents

SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)
         
Date: May 28, 2002   /s/ Mark A. Prygocki, Sr.
    Name:   Mark A. Prygocki, Sr.
    Title:   Executive Vice President, Chief
Financial Officer, Corporate Secretary
and Treasurer

  EX-99.1 3 p66647exv99w1.htm EX-99.1 exv99w1

 

EXHIBIT 99.1

(MEDICIS LETTERHEAD)

CONTACT:
Libby Ivy, Director, Investor Relations & Corporate Communications, (602)808-3854

MEDICIS ANNOUNCES OFFERING OF $350 MILLION OF
CONTINGENT CONVERTIBLE SENIOR NOTES DUE 2032

SCOTTSDALE, Arizona—May 28, 2002—Medicis (NYSE:MRX) today announced that it intends to raise approximately $350 million through an offering of 30-year contingent convertible senior notes (the “Notes”) in a private placement pursuant to Rule 144A under the Securities Act of 1933 (the “Act”). The Company also intends to grant the initial purchasers an option to purchase up to an additional $50 million of Notes. Medicis expects to use the net proceeds from the offering: (1) to fund the purchase of $125 million of Class A common stock sold short by purchasers of the Notes concurrently with their purchases of Notes (2) for future acquisitions and (3) for general corporate purposes.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. The Notes have not been registered under the Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

The statements in this press release regarding the timing of the proposed private placement and its terms are forward-looking statements that involve risks and uncertainties including, but not limited to, market conditions and the price and market for the securities to be offered.

# # #

GRAPHIC 4 p66647p66647a01.gif GRAPHIC begin 644 p66647p66647a01.gif M1TE&.#EAH0*L`/<``````/______________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________RP`````H0*L```(_@`#"!Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;- MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EV*$H#3D4^92IU*M:K5JU2=`H`:%:O7 MKV##BAV[4>M6KF?)JEW+MJU;HV:UDHQK,.W;NWCSZMV+,6[7D'X+_N5+N+#A MPV&[^AT,C+K8K[AP@<:52Y].O:5< MXM:;OZ[.O;MWP,0A_L-V#5W\]_/HT[<.'[TD>_/JX\L__QYF_?GX\W]G'_.^ M_O\`(L>??0,&:."!LX6GT781^8?@@Q!.]I2"?3$(T7WM1:CAAFJ]EV%#ITWD MX8<%:CB:#/*"..-.")EHT2FU4AACG5AE]&(\`') M88H-7F44B-.*4!PG)$8U<&EFE0U<&4&:28W+9 M7$>:%<(9)GD=SNIDCE#PR1V*7.^KYF)1?+BGHBWS2F5:>9`9Z M*)8K+FCHHRCKDI*@>:6FJ_K+] MV>FIK1)$JT69UJKAJ$P2VBNAI>KY7(7!ZOH?KZ9&>BEVN8;J):ZL&HM@D[\J MN^RFM6*KJ*Q:MIE3B-Q*.Q.RUS8[*[G&7GEG1>;&N:ZMZPX+:;ORBKLV363)(E[U"[1OPP`XS++#!_Z(9+L6`$KPPK$4F M#!F_$M?D\,/SXALRQ8OZ:C&:"1V,LGD;:ZEIRR2?G-V^[.)L\YSO;LLRS8;& MC#!\'K=7L\TWH[NMMO;FV3.IW$;KLLOSTCRSU5B-K/767'?MM=FF,9]=M]]UX/PVQ_M`^\CUTWH";W:&%>KL=-9'= MPITIJ'Y#1W?@D$N#B>9T[9S?#I3ENB/.N_(0 ME\O\T,)'J7;5\"Y-]51,NW?KWGG?VWO7+^>\?9S-/WO1]&8.3G3RL%;_:?$I MOT8R\-R+W13\L]O=_]#_8DY9+(_A"Z,>?P!&!7[0@XSIHQ/9);RQZ MM%X=Q1C((-VQDX+\T*E.9\A*)C"1AZ1A!4$YE$?N+I+GFV3C3"G'1O9$D1$, MXP;WV$<\O?)I_Y*7*=>H0EV6C%BL;!@4PU;"@%5LF'ZYC*9F<9HBI-5ZUP*-J]I36;N3YK$_C3> M",$T2FZ.$Y"#M&(\E6).8`[T53Z\5@JI6FYSD\_[$CH? MZLT>KO2C"LUG376$T:'2B:0AQ:E$O8?00"G5ES>]H5'KLE-&Q@RFQV07F424 M3;?HTZ-]8J=5;?E)DU@T5205XTO(Z<2IW@6F\1JHF,X24?.)-858Q2M9*3K( MBW*20`!=XFJP2DBYOJE^8/4<&<U7K8\OINJ]19%_TEM6V[_FL^[]G:4Q8+?K!="09SRY?5 MGO51KS7M41<+6LO*,+24K2Q'A5* M5C<:Y.U>6BM32E77ND#];';-^MWU)O>(CCRD>/-2VY\*ZKRUS5XV[_=EAR4A2Q5<7-I.UX;;^UZ!4[+#";\EO^K-5JSZVZU=-EB[ MI]V<.@6<00);N"T8=BC0!M:IZ+$82[&-7SGU.C9)_:]0N;'FB06(W.,NB8@D M+K$;=UQ5'*/W27\%4YABV1*^N29](TR*5) MI8K?^F#1VCBXCDNR_M'4[.1M1GFX4GZR8E=EYLEN\&);]G&7K87"/`L9BO8M M#(9U5R@YTP]27:(@7;]:U$9#F8J;41*B8>PWX[7XTB^T\Y5M2-$/L_?(-N69 M^L:LV[HB&,6@5B..D6RK:/OYP+V&=,M>#6Y+1UG<;VZR!,'M M;3D3G-?6#G8RHXI9AA>4V`$M\T8Y6VNAR3O,INT>.NL48SI7^X432O2O_K5= MG%W3\=_Y)O>NVP=P6IO\Y0BG,[IS]LF3R;!#F.FW;E.S?6Y=C9?=K);,GX]]*DKAGJW=RE9ZW.5^ MBT36_)2NL^IS7JAR*YYTU)/.QLY#ED2XG"_.4_WVPA)^]$PEL>KWM/+68/O: MR)>_IA/CU0RPE[0-_P(,F(^\?M'3F(!KNLM=_LR!2,5U$,)TEL1M*L=R)/=D&KAOU75=%A=% M&%@J2A4LN7=_,T=_K&5Z+(AQ%LA.&)B!HB9K(P=SF)8[QU-^'Y=W*'=^`<1= M3/*`MK5=+?A?"A),,5B!^P=_/28?B(5^D%9T,>>!#[1O56AM4%8\7/AJ+4=S M#'@UZQ9_,]A5$:@SV"4^9ZA_A_)5&_B!N:9P!R%T5>& MRG>$U2>#-4AZE)-A_K>T??L5A>I15-/T?$4'B8QV10;G+T1W4T@7;B-H96,8 M>X)HA,%7B&-U@6#7A*AGBIVV>0L"%KOG3F:(3XH8-FE8>5_VA/@GB@ZHBNN3 M&*\(3W@&>;985MAG>;68?X1HC,J%A+K81,3DB9_XC*'(B#7'5T,7C$Z(C.ZW MC))!;Y3$6!&'BTDH=F:D,K&(96U89]JH6K\X2TGU;*B(AJ561^]2CA,'CH"8 MCL?7?$@W;/7S8@CCC_TW439W,'+54>_8/"[8711GC]QGC?>(CW&H@R"'@.8F MD01'A\"V<.W(*$=C:@6D3$7_H9# MV(S^Z&E$^&G8.(T*N9#26(\]B8ZZ"(=^"((EAW`PJ9(8:9$+.(J89I/9B),F M&8X`%9#GV'M2\V<0"9,M5Y0O)FY,5G(Z*)-3QI14-HB`Y&`_F3Y'>#Q5.7D= M@Y7XJ)70%QQ%28=#R8$5B8/M]V'3Y9%5^9%JN99LZ9":-#W(U9:K!W->.7XM MJ9>.B)=&J91BR)0&V$FKF9,'A)8#.6*( MR9)W=EVGF)9N@D>TN6=6N4##*8K>19P(Z8UO_I.3Y`F- M,G=C4`F=Y16;O9*,G=.0GVEXQ3:?XP)*$U:=0B>5#4DZ0*>(;36.*8:=<8F' MW28R]NE6^-E8;'6+71='A0=-*_1=X/F9SJE)$V>.QK1COIAS]PEM2,52WZAV MOB6@):)PDE9Q=QF"L_=UCAAUWG1I=EUR.23('-J+I:*$B6C<%>0\P16*U5O_0,] M2JJD1MF%%7FB4XA^=(F439J:$-:@`'IJL>2A^DEZY3.=G\.9J+2(1I.<)@)P M6ZF`1CJ7*7<]`XAF_G+)IOPIG$P#.5-I1'"ZDZ`6,72J.A]3IW?'IPKHE3-D MEVFJ+DN*D4PZE(*II>J)+I%#C0!D9!S7HQB:(GW'I;=CJ948J-F&,9)XB=GI M;_MHHO$)0[O:J[Y*:+\:K/$)I,):K&I"HL::K(<5E(ZKN1:KN9ZKNB:KNJZK>&ZKN[ZKO`:K_(Z MK_1:KP.$I_::K_JZK_S:K_[ZK^"*KP`[L`1;L`9[L`CKK>V:L`S;L`[[L!`; ML8,IL11;L19[L1CKK@N;L1S;L1[[L2"KAC08LB1;LB9[LAF[L2B[LBS;_K(N M2Z\J^[(R.[,T6[/6&K,VF[,ZN[,\*[*DV+-`&[1".[1T2;1&>[1(:[,XF[1, MV[1.V[!+^[12.[54:Z]16[58ZZ]WI$K+:7[`.I]@MRS$TYH\:'6_LZ&@TTOS M*(3Z=XA9^[85.VF#MW.T.'@4][7@8K=RRVB1R*(`2*M^>U=^&XG8XWM]>[A> MM[=\Z[-PV[@0JXF3.*=V.[D1F7Y*]W]T:XF*N[B(A:*`2XN?I;?E,[F4F[>G M<:60JS57Z[BL&Z^Z-KA"2;J@2[B'6[F5FY&4"W*7^Z&A>XFG&[B\]KNEYU>( MVX]?][-NV[K*6["O6[>$J[NEQWJ`>TQ6R+?-_@NZT,NI@CN\$HB]E`>[QTLC MG5NKN$L^`KN\Z"NOL$>)'*D=(8B7[TMR$QNYX"MKFL&$!F5Q]XN_,2I;<]JV M!32RZ3O`[WJ]B+NW`JR)3!J_]MMT[`N\@E>\$FS`OPN2W^N\#@QOG"N)%#PR MJTO`(,RM!FS!B7N!"NR!M9N2=4O!A;O"#%9_OCNW.77!&_QRE1:CL1O#D`K` M(=S#Y$J#+5S"[@MUN?JW+EJZE1?$FNM7O6N),BR\WYNZ4@R[V9NZ'GR^/IS% MW3JR19S$O(O#F^NY5%S%1SRX,PS%H@O#].N]7LRB9RS$;7RO/*S%='RM0<2U MQ4:0[+=A>\R8R>=JC@5Z7APCC/J59J[784`ER&#IH^12QX[\R"#\P9`\R93< MLY) -----END PRIVACY-ENHANCED MESSAGE-----